Sionna Therapeutics Inc. (SION)
NASDAQ: SIONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SION stock chart
Technical analysisKey statistics
All statistics- Market cap
- $127.79M
- EPS (TTM)
- -$2.43
- Dividend yield
- None
- 52-week range
- 2.75 – 54.97
- Day range
- 2.76 – 3.06
- Volume / Avg
- 547.66K / 1.12M
- Beta
- —
- Shares outstanding
- 45.24M
52-week range
SION stock today
Shares of Sionna Therapeutics (SION) finished lower on Nov 20 at $2.83, a drop of 4.88% or $0.145 per share, versus the S&P 500's 3.70% decline. Trading was light, with 547.66K shares changing hands, about 49% of the average daily volume. Shares are 94.9% below their 52-week high of $54.97, set on Aug 7, 2026 and 2.6% above the 52-week low of $2.75, near the bottom of the past year's range.
SION is down 93.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 93.5%. Sionna Therapeutics has posted a net loss over the last twelve months (EPS of -$2.43), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sionna Therapeutics
Company profileSionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael Cloonan M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 59
- IPO year
- 2025
- Website
- sionnatx.com
Financial highlights
Full financialsSionna Therapeutics reported a net loss of $75.3 million, compared with a loss of $61.7 million a year earlier. Diluted earnings per share came in at -$1.88.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-75.27M | $-61.69M |
| EPS (diluted) | $-1.88 | $-15.99 |
Analyst forecast
ForecastConsensus (12 analysts)
hold
Avg. price target
$21.00+643.36%
- Strong buy 0
- Buy 2
- Hold 10
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.72 vs $-0.62
- Surprise
- -16.13%
SION news
All SION news- Sionna Posts Wider Loss In Q3 With 46% Workforce Cut; Phase 2 Cystic Fibrosis Trial Set For Q1 2027NasdaqSION, LEN.B
- Sionna Therapeutics Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 YearsNasdaqVRTX, CRSP, SION
- Sionna Therapeutics to Participate in Upcoming November 2026 Investor ConferencesGlobeNewswire
- Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferenceGlobeNewswire
- Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even MoreNasdaqVRTX, ABBV, KRYS, SION
Sionna Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MGNXMacroGenics Inc. | 1.96 | -1.01% | $125.26M | vs SION |
| ZNTLZentalis Pharmaceuticals Inc. | 1.36 | 0.00% | $133.64M | vs SION |
| MSLESatellos Bioscience Inc. | 5.68 | -2.07% | $120.51M | vs SION |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs SION |
| ADAGAdagene Inc. ADR | 1.76 | -12.44% | $118.17M | vs SION |
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs SION |
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs SION |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs SION |
Indexes, lists and sector
Sionna Therapeutics stock FAQ
What is Sionna Therapeutics's stock price today?
SION last traded at $2.83 as of Nov 20, 4:00 PM EST, down 4.88% on the day. Prices are delayed at least 15 minutes.
Who is Sionna Therapeutics's CEO?
Mr. Michael Cloonan M.B.A. is the chief executive officer of Sionna Therapeutics Inc., which has about 59 employees.
What is the SION 52-week high?
The 52-week high for SION is $54.97 and the 52-week low is $2.75. The stock is currently 94.9% below its high.